Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Liposarcoma · Prostate Cancer · Advanced Breast Cancer · NSCLC (Non-small Cell Lung Cancer) · Colorectal Cancer
De qué trata este estudio
El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.
- Tipo de estudio
- De intervención
- Fase
- Fase 2
- Rango de edad
- 18 años - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- No aceptados
- Participantes
- 430 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort.
Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide.
The Giredestrant Combination Cohort will evaluate PF-07220060 in combination with giredestrant.
In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion.
In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively).
In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from Part 1A will be conducted.
In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI).
In Part 1F, escalating doses of PF-07220060 will be administered in combination with enzalutamide.
In Part 1G, PF-07220060 will be administered in combination with tamoxifen to determine the RDE.
Part 2A is an expansion cohort for PF-07220060 in combination with fulvestrant and will explore more than one dose of PF-07220060.
Part 2B and Part 2C are expansion cohorts for PF-07220060 in combination with letrozole and fulvestrant, respectively.
Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy.
Part 2F is an expansion cohort for PF-07220060 in combination with tamoxifen. The Giredestrant Combination Cohort Group A will determine the tolerable dose of PF-07220060 in combination with giredestrant. In Group B, additional participants will be enrolled at the tolerable dose to further assess safety and PK.
The China and Japan monotherapy cohorts will evaluate safety, tolerability, and PK of PF-07220060 as single agent in Chinese and Japanese participants, respectively.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria
- Part 1: Breast Cancer (BC)
- Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC
- Part 1A/Part 1D/Part 1E also include: Refractory HR-positive/HER2-positive BC
- Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests
- Part 1F: prostate cancer
- Part 1G: HR-positive/HER2-negative BC
- Part 2A, 2B, 2C, 2E, and 2F: HR-positive/HER2-negative BC
- Part 1D: metastatic castration resistant prostate cancer
- Giredestrant Combination Cohort: ER-positive/HER2-negative BC
- Prior systemic Treatment
- Part 1: HR-positive/HER2-negative BC
- At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator
- HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatment of approved HER2 targeting therapy
- Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available
- Part 2A and 2E: at least 1 line of standard of care (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo is allowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed
- Part 2B: no prior systemic anti-cancer therapies for advanced/metastatic BC
- Part 2C:
- Progressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre or perimenopausal, or
- Progressed while on or within 1 month after the endo the prior aromatase inhibitor therapy for advanced/metastatic BC if postmenopausal or prior endocrine treatment for advanced/metastatic BC if pre or perimenopausal
- One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy
- Part 1G and 2F: at least 2 lines of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy
- Giredestrant Combination Cohort: at least 1 (no more than 3) prior line(s) of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy
General Inclusion Criteria
- All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- Adequate renal, liver, and bone marrow function
Exclusion Criteria:
- Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor
- Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway
- Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease
- Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
- Major surgery or radiation within 4 weeks prior to study intervention
- Last anti-cancer treatment within 2 weeks prior to study intervention; Part 1G and 2F: tamoxifen treatment within 35 days of Day -4
- Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
- Part 1G and 2F: history of or current pulmonary embolism or deep vein thrombosis
- Giredestrant Combination Cohort: history (within 6 months of screening) of or presence of idiopathic symptomatic bradycardia or resting heart rate \<50 bpm at screening
- Pregnant or breastfeeding female participant
- Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease
Tratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- Sin asignación al azar
- Enmascaramiento
- Sin enmascaramiento
1A Monotherapy Escalation Arm 1
PF-07220060 Monotherapy Escalation
Drug: PF-07220060
1A Monotherapy Escalation Arm 2
PF-07220060 Monotherapy Escalation
Drug: PF-07220060
1A Monotherapy Escalation Arm 3
PF-07220060 Monotherapy Escalation
Drug: PF-07220060
1A Monotherapy Escalation Arm 4
PF-07220060 Monotherapy Escalation
Drug: PF-07220060
1A Monotherapy Escalation Arm 5
PF-07220060 Monotherapy Escalation
Drug: PF-07220060
1B Combination Dose Finding Arm 1
PF-07220060 with Letrozole combination Escalation
Drug: PF-07220060 · Combination Product: Letrozole
1B Combination Dose Finding Arm 2
PF-07220060 with Letrozole Combination Escalation
Drug: PF-07220060 · Combination Product: Letrozole
1C Combination Dose Finding Arm 1
PF-07220060 with Fulvestrant Combination Escalation
Drug: PF-07220060 · Combination Product: Fulvestrant
1C Combination Dose Finding Arm 2
PF-07220060 with Fulvestrant Combination Escalation
Drug: PF-07220060 · Combination Product: Fulvestrant
1D Monotherapy Food Effect
PF-07220060 Monotherapy Food Effect
Drug: PF-07220060
1E DDI Cohort
PF-07220060 DDI with Midazolam
Drug: PF-07220060 · Other: Midazolam
1F Combination Dose Finding
PF-07220060 with Enzalutamide Escalation
Drug: PF-07220060 · Combination Product: Enzalutamide
1G Combination Dose Finding Arm 1
PF-07220060 with Tamoxifen Combination De-Escalation
Drug: PF-07220060 · Combination Product: Tamoxifen
2A Combination Dose Expansion
PF-07220060 with fulvestrant combination expansion
Drug: PF-07220060 · Combination Product: Fulvestrant
2B Combination Dose Expansion
PF-07220060 with Letrozole Combination Expansion
Drug: PF-07220060 · Combination Product: Letrozole
2C Combination Dose Expansion
PF-07220060 with fulvestrant Combination Expansion
Drug: PF-07220060 · Combination Product: Fulvestrant
2E Combination Dose Expansion
PF-07220060 Monotherapy OR PF-07220060 plus fulvestrant combination therapy
Drug: PF-07220060 · Combination Product: Fulvestrant
2F Combination Dose Expansion
PF-07220060 with Tamoxifen Combination Expansion
Drug: PF-07220060 · Combination Product: Tamoxifen
Giredestrant Combination Cohort (Group A)
PF-07220060 with Giredestrant Combination
Drug: PF-07220060 · Combination Product: Giredestrant
Giredestrant Combination Cohort (Group B)
PF-07220060 with Giredestrant Combination
Drug: PF-07220060 · Combination Product: Giredestrant
PF-07220060 DRUG
CDK4 inhibitor
Letrozole COMBINATION_PRODUCT
Endocrine Therapy
Fulvestrant COMBINATION_PRODUCT
Endocrine Therapy
Midazolam OTHER
Benzodiazepine
Enzalutamide COMBINATION_PRODUCT
Androgen Receptor inhibitor
Giredestrant COMBINATION_PRODUCT
Endocrine Therapy
Tamoxifen COMBINATION_PRODUCT
Endocrine Therapy
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Number of participants with dose limiting toxicities in the Dose Escalation or De-escalation Portion
Plazo: At the end of Cycle 1 (each cycle is 28 days)
First cycle (28 days) dose limiting toxicities
Incidence of clinically significant AEs
Plazo: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Adverse Events
Incidence of clinically significant laboratory assessments
Plazo: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
safety laboratory abnormalities
Incidence of clinically significant abnormal vital and ECG parameters
Plazo: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
vital signs and heart rate corrected QT interval
Maximal Plasma Concentration (Cmax) of PF-07220060 given with and without food
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D)
Time to Maximum Plasma Concentration (Tmax) of PF-07220060 given with and without food
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D)
Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point (AUClast) of PF-07220060 given with and without food
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D)
Maximal Plasma Concentration (Cmax) of Midazolam with and without PF-07220060
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E)
Time to Maximum Plasma Concentration (Tmax) of Midazolam with and without PF-07220060
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E)
Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Timepoint (AUClast) of Midazolam with and without PF-07220060
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E)
Steady State Maximal Concentration (Cmax,ss) of PF-07220060
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of PF-07220060
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of PF-07220060
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)
Steady State Minimum Plasma Concentration (Cmin,ss) of PF-07220060
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)
Steady State Maximal Concentration (Cmax,ss) of Giredestrant
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Giredestrant
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of Giredestrant
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)
Steady State Minimum Plasma Concentration (Cmin,ss) of Giredestrant
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)
Medidas secundarias
Single Dose: Maximal Plasma Concentration (Cmax) in the Dose Escalation and Dose Finding portion
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1F)
Single Dose: Time to Maximum Plasma Concentration (Tmax) in the Dose Escalation and Dose Finding portion
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1F)
Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point Within the Dose Interval (AUClast) in the Dose Escalation and Dose Finding portion
Plazo: Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1F)
Multiple Dose: Steady State Maximal Concentration (Cmax,ss) in the Dose Escalation and Dose Finding portion
Plazo: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)
Multiple Dose: Steady State Time to Maximum Plasma Concentration (Tmax,ss) in the Dose Escalation and Dose Finding portion
Plazo: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCt,ss) in the Dose Escalation and Dose Finding portion
Plazo: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)
Multiple Dose: Steady State Minimum Plasma Concentration (Cmin,ss) in the Dose Escalation and Dose Finding portion
Plazo: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)
Steady State Peak Concentration of Enzalutamide and N-desmethyl Enzalutamide
Plazo: Cycles 1 - 12 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for enzalutamide (Part 1F)
Steady State Trough Concentration of Enzalutamide and N-desmethyl Enzalutamide
Plazo: Cycle 3 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for enzalutamide (Part 1F)
Tumor Response per RECIST v1.1 and per PCGW3
Plazo: baseline up to approximately 24 months
Per RECIST v1.1 (all cohorts except for Part 1F); per PCWG3 (Part 1F)
Duration of Response (DOR)
Plazo: baseline up to approximately 24 months
Per RECIST v1.1
Progression Free Survival (PFS)
Plazo: baseline up to approximately 24 months
PFS per RECIST v.1.1
Clinical Benefit Rate (CBR)
Plazo: baseline up to approximately 24 months
CBR per RECIST v1.1
PSA50
Plazo: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Part 1F
Incidence of clinically significant AEs
Plazo: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Adverse Events (Giredestrant Combination Cohort)
Incidence of clinically significant laboratory assessments
Plazo: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Safety laboratory abnormalities (Giredestrant Combination Cohort)
Steady State Minimal Concentration (Cmin,ss) of Tamoxifen, 4-hydroxy-tamoxifen, N-desmethyltamoxifen, and Endoxifen
Plazo: Cycle 2 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for tamoxifen and metabolites (Parts 1G and 2F)
Metabolite to Parent Ratio of Minimal Concentration (MRCmin) of 4-hydroxy-tamoxifen, N-desmethyltamoxifen, and Endoxifen
Plazo: Cycle 2 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for tamoxifen and metabolites (Parts 1G and 2F)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCt,ss) of Tamoxifen, 4-hydroxy-tamoxifen, N-desmethyltamoxifen, and Endoxifen
Plazo: Cycle 2 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for tamoxifen and metabolites (Parts 1G and 2F)
Steady State Peak Concentration of PF-07220060
Plazo: Cycle 1 (each cycle is 28 days) for Part 2A/2B/2C/2E; Cycle 2 (each cycle is 28 days) for Part 2F
Pharmacokinetic (PK) assessments for PF-07220060 (Part 2A, 2B, 2C, 2E, 2F)
Steady State Trough Concentration of PF-07220060
Plazo: Cycle 1 (each cycle is 28 days) for Parts 2A/2B/2C/2E; Cycle 2 (each cycle is 28 days) for Part 2F
Pharmacokinetic (PK) assessments for PF-07220060 (Parts 2A, 2B, 2C, 2E, 2F)
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (39)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
39 centros
Ellison InstituteLos Angeles, California, United StatesReclutando
Smilow Cancer Hospital - Yale New Haven HealthNew Haven, Connecticut, United StatesReclutando
Yale-New Haven Hospital-Yale Cancer CenterNew Haven, Connecticut, United StatesReclutando
Smilow Cancer Hospital Phase 1 UnitNew Haven, Connecticut, United StatesReclutando
Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOPNew Haven, Connecticut, United StatesReclutando
Smilow Cancer Hospital - TrumbullTrumbull, Connecticut, United StatesReclutando
Brigham & Women's HospitalBoston, Massachusetts, United StatesActivo, sin reclutamiento
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesActivo, sin reclutamiento
Dana Farber Cancer Institute- Chestnut HillNewton, Massachusetts, United StatesActivo, sin reclutamiento
START MidwestGrand Rapids, Michigan, United StatesReclutando
Sarah Cannon Research Institute - PharmacyNashville, Tennessee, United StatesReclutando
SCRI Oncology PartnersNashville, Tennessee, United StatesReclutando
The University of Texas MD Anderson Cancer CenterHouston, Texas, United StatesReclutando
The University of Texas, MD Anderson Cancer Center - West HoustonHouston, Texas, United StatesReclutando
Hospital Británico de Buenos AiresCiudad Autónoma de Buenos Aires, Buenos Aires, ArgentinaActivo, sin reclutamiento
Fundación Cenit Para La Investigación En NeurocienciasCABA, Ciudad Autã³noma de Buenos Aires, ArgentinaActivo, sin reclutamiento
Fundación RespirarBuenos Aires, ArgentinaActivo, sin reclutamiento
Clínica Universitaria Reina FabiolaCórdoba, ArgentinaActivo, sin reclutamiento
Fundación CORI para la Investigación y Prevención del CáncerLa Rioja, ArgentinaActivo, sin reclutamiento
Cancer Hospital Chinese Academy of Medical ScienceBeijing, Beijing Municipality, ChinaActivo, sin reclutamiento
Henan Cancer HospitalZhengzhou, Henan, ChinaActivo, sin reclutamiento
Hubei Cancer HospitalWuhan, Hubei, ChinaActivo, sin reclutamiento
The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, Shanxi, ChinaActivo, sin reclutamiento
Sir Run Run Shaw Hospital, Zhejiang University School of MedicineHangzhou, Zhejiang, ChinaActivo, sin reclutamiento
Vseobecna fakultni nemocnice v PrazePrague, CzechiaActivo, sin reclutamiento
National Cancer Center Hospital EastKashiwa, Chiba, JapanActivo, sin reclutamiento
COI Centro Oncologico Internacional S.A.P.I. de C.V.Mexico City, Mexico City, MexicoActivo, sin reclutamiento
Hospital MAC Periferico SurMexico City, Mexico City, MexicoActivo, sin reclutamiento
INCANMexico City, Mexico City, MexicoActivo, sin reclutamiento
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"Monterrey, Nuevo León, MexicoActivo, sin reclutamiento
Hospital ReformaOaxaca City, Oaxaca, MexicoActivo, sin reclutamiento
Oaxaca Site Management OrganizationOaxaca City, MexicoActivo, sin reclutamiento
Onkologicky ustav sv. Alzbety, s.r.o., Interna klinika VSZaSP a OUSABratislava, SlovakiaActivo, sin reclutamiento
Narodny onkologicky ustavBratislava, SlovakiaActivo, sin reclutamiento
Fakultna nemocnica s poliklinikou Nove ZamkyNové Zámky, SlovakiaActivo, sin reclutamiento
Cancer Research UK Edinburgh CentreEdinburgh, Edinburgh, CITY of, United KingdomActivo, sin reclutamiento
St Bartholomew's HospitalLondon, London, CITY of, United KingdomActivo, sin reclutamiento
Sarah Cannon Research Institute UKLondon, United KingdomActivo, sin reclutamiento
The Christie Hospital NHS Foundation TrustManchester, United KingdomActivo, sin reclutamiento
Equipo y fechas
- Patrocinador principal
- Pfizer
- Inicio del estudio
- 23 sept 2020 Real
- Finalización primaria
- 7 oct 2029 Estimado
- Finalización del estudio
- 7 oct 2029 Estimado
- Primera publicación
- 21 sept 2020 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026